Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076303 · ClinicalTrials.gov registry record
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
A clinical trial of Glaucoma and Primary Open Angle Glaucoma, sponsored by Brian Shafer.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT07076303 is a study of Glaucoma and Primary Open Angle Glaucoma that is actively recruiting participants, run by Brian Shafer. The registered enrollment target is 60 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07076303, a study of Glaucoma and Primary Open Angle Glaucoma, is actively recruiting participants, sponsored by Brian Shafer.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss. Current treatment strategies often involve medications, which can be challenging for patients due to adherence issues and side effects. Direct Selective Laser Trabeculoplasty (DSLT) represents a potential surgical alternative for managing IOP in patients with naive, untreated glaucoma. This study aims to evaluate the efficacy of DSLT in achieving significant IOP reduction without the need for postoperative medications. Unmet Medical Need: Overview of DSLT Direct Selective Laser Trabeculoplasty (DSLT) is an emerging technology in glaucoma management that combines laser techniques to reduce intraocular pressure (IOP). While it works off the auspices of a previous technology (SLT), the method of delivery is significantly different. Current Research Landscape Most existing studies focus on patients who have already received other forms of treatment or who have more advanced glaucoma. This creates an unmet need to evaluate how DSLT can be effectively integrated into the management of patients at the very beginning of their glaucoma journey. Understanding its efficacy in this population is crucial for establishing best practices and improving long-term outcomes. Interventional Glaucoma Management vs. Standard of Care Standard of care for newly diagnosed glaucoma typically involves medications, such as topical prostaglandin analogs, which can have side effects and may not be effective for all patients. In contrast, interventional glaucoma management-such as DSLT-offers a potentially more direct approach to lowering IOP without the need for ongoing medication. Investigating DSLT in this context could lead to a paradigm shift in how newly diagnosed patients are managed, reducing their reliance on medications and potentially improving adherence and quality of life. Conclusion Addressing this research gap will not only help
Conditions Studied
Interventions
- DEVICE Direct Selective Laser Trabuloplasty
Study Locations (1)
Pennsylvania
- Shafer Vision Institute - Plymouth Meeting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-03-11 |
| Est. Completion | 2026-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07076303
The ClinicalTrials.gov registry entry for NCT07076303 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (93% lower). The listed sponsor is Brian Shafer, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Direct Selective Laser Trabuloplasty is the first listed.
NCT07076303 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07076303 about?
NCT07076303 is a clinical study titled "A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients". Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss. Current treatment strategies often involve medications, which can be challenging for patients due to adherence issues and side effects. Direct Selective L...
What is the current status of trial NCT07076303?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2002-03-11. Estimated completion is 2026-06-01.
What conditions does trial NCT07076303 study?
This clinical trial studies the following conditions: Glaucoma, Primary Open Angle Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension.
What interventions are being tested in trial NCT07076303?
The interventions under investigation include: Direct Selective Laser Trabuloplasty (DEVICE).
Who is sponsoring clinical trial NCT07076303?
This trial is sponsored by Brian Shafer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076303 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Eye Pressure Lowering Surgery
RECRUITING
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.